Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro

被引:71
作者
Correale, P
Cusi, MG
Del Vecchio, MT
Aquino, A
Prete, S
Tsang, KY
Micheli, L
Nencini, C
La Placa, M
Montagnani, F
Terrosi, C
Caraglia, M
Formica, V
Giorgi, G
Bonmassar, E
Francini, G
机构
[1] Univ Siena, Sch Med, Dept Human Pathol & Oncol, Oncol Sect, I-53100 Siena, Italy
[2] Univ Siena, Sch Med, Dept Human Pathol & Oncol, Sect Pathol, I-53100 Siena, Italy
[3] Univ Siena, Sch Med, Sect Virol, Dept Mol Biol, I-53100 Siena, Italy
[4] Univ Siena, Sch Med, Giorgio Segre Dept Pharmacol, I-53100 Siena, Italy
[5] Natl Canc Inst, Fdn Pascale, Expt Oncol Unit, Naples, Italy
[6] Univ Roma Tor Vergata, Dept Neurosci, Med Oncol & Pharmacol Sect, Rome, Italy
[7] NCI, Expt Oncol Sect, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA
关键词
D O I
10.4049/jimmunol.175.2.820
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gemcitabine, oxaliplatin, leucovorin, and 5-fluorouracil (GOLF) is a novel multidrug regimen inducing high levels of necrosis and apoptosis in colon carcinoma cells. This regimen is also able to promote a process of Ag remodeling including up-regulation of immunotherapy targets like carcinoembryonic Ag (CEA), thymidylate synthase (TS). We have conducted a preclinical study aimed to investigate whether these drug-induced modifications would also enhance colon cancer cell immunogenicity. Several CTL lines were thus generated by in vitro stimulating human HLA-A(*)02.01(+) PBMCs, from normal donors and colon cancer patients, with autologous dendritic cells cross-primed with cell lysates of colon cancer cells untreated, irradiated, or previously exposed to different drug treatments including the GOLF regimen. Class I HLA-restricted cytolytic activity of these CTL lines was tested against colon cancer cells and CEA and TS gene transfected target cells. These experiments revealed that CTLs sensitized with GOLF-treated cancer cells were much more effective than those sensitized with the untreated colon carcinoma cells or those exposed to the other treatments. CTL lines sensitized against the GOLF-treated colon cancer cells, also expressed a greater percentage of T-lymphocyte precursors able to recognize TS- and CEA-derived peptides. These results suggest that GOLF regimen is a powerful antitumor and immunomodulating regimen that can make the tumor cells a suitable means to induce an Ag-specific CTL response. These results suggest that a rationale combination of GOLF chemotherapy with cytokine-based immunotherapy could generate a chemotherapy-modulated Ag-specific T-lymphocyte response in cancer patients able to destroy the residual disease survived to the cytotoxic drugs.
引用
收藏
页码:820 / 828
页数:9
相关论文
共 53 条
[1]  
Aarts WM, 2002, CANCER RES, V62, P5770
[2]   Making use of the primary tumour [J].
Baars, A ;
Buter, J ;
Pinedo, HM .
BIOESSAYS, 2003, 25 (01) :79-86
[3]   Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway [J].
Basu, S ;
Binder, RJ ;
Suto, R ;
Anderson, KM ;
Srivastava, PK .
INTERNATIONAL IMMUNOLOGY, 2000, 12 (11) :1539-1546
[4]   CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin [J].
Basu, S ;
Binder, RJ ;
Ramalingam, T ;
Srivastava, PK .
IMMUNITY, 2001, 14 (03) :303-313
[5]  
BEDIKIAN AY, 1978, CANCER, V42, P2169, DOI 10.1002/1097-0142(197811)42:5<2169::AID-CNCR2820420513>3.0.CO
[6]  
2-V
[7]   Dendritic cells [J].
Bell, D ;
Young, JW ;
Banchereau, J .
ADVANCES IN IMMUNOLOGY, VOL. 72, 1999, 72 :255-324
[8]   Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes [J].
Bergmann-Leitner, ES ;
Abrams, SI .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (09) :445-455
[9]  
BONMASSAR E, 1972, CANCER RES, V32, P1446
[10]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51